SPY749.60−0.63%QQQ674.25−0.83%BTC/USD67,047.47−1.74%DIA521.21−0.37%GLD355.70+0.07%TLT79.42+0.05%

Xeris Biopharma Holdings Inc

XERSNASDAQ

Trade with Public

$16.66

0.010.06%

At close: Nov 13, 4:00 PM EST

$16.67

0.010.06%

After Hours: 5:31 PM EST

Overview News Charts Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Xeris Biopharma Holdings (XERS) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Xeris Biopharma Holdings (XERS) stock.

Analyst Consensus — 7 Analysts

7Buy

# Analysts7

Latest Upgrades and Downgrades for Xeris Biopharma Holdings Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
—	Barclays	Glen Santangelo	PT Raise	Overweight	$14→$18
—	Oppenheimer	Leland Gershell	PT Raise	Outperform	$18→$21
—	Piper Sandler	David Amsellem	PT Raise	Neutral	$8→$12
—	HC Wainwright & Co.	Brandon Folkes	PT Raise	Buy	$10→$18
—	Barclays	Glen Santangelo	PT Raise	Overweight	$12→$14
—	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$12→$16
—	Barclays	Glen Santangelo	PT Raise	Overweight	$9→$12
—	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
—	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
—	Barclays	Glen Santangelo	Initiate	Overweight	$9
—	Oppenheimer	Leland Gershell	Maintained	Outperform	$18
—	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
—	Piper Sandler	David Amsellem	PT Raise	Neutral	$6→$8
—	Oppenheimer	Leland Gershell	PT Raise	Outperform	$8→$18
—	HC Wainwright & Co.	Brandon Folkes	Maintained	Buy	$10
—	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$7→$9
—	HC Wainwright & Co.	Brandon Folkes	Assumes	Buy	$10
—	Craig-Hallum	Chase Knickerbocker	PT Raise	Buy	$7→$11
—	Oppenheimer	Leland Gershell	PT Raise	Outperform	$7→$8
—	Leerink Partners	Roanna Ruiz	PT Raise	Outperform	$6→$7

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings (XERS) Stock Price Target 2026

Latest Upgrades and Downgrades for Xeris Biopharma Holdings Stock

Xeris Biopharma Holdings (XERS) Stock Price Target 2026

Latest Upgrades and Downgrades for Xeris Biopharma Holdings Stock

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PRO
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

People Also Watch

People Also Watch

Analyst Ratings News

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PRO
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

Xeris Biopharma Holdings Inc

Xeris Biopharma Holdings (XERS) Stock Price Target 2026

Latest Upgrades and Downgrades for Xeris Biopharma Holdings Stock

Xeris Biopharma Holdings (XERS) Stock Price Target 2026

Latest Upgrades and Downgrades for Xeris Biopharma Holdings Stock

Analyst Ratings News

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PROOppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PROPiper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PROHC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PROLeerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

People Also Watch

People Also Watch

Analyst Ratings News

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PROOppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PROPiper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PROHC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PROBarclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PROLeerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PRO
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Oppenheimer Reiterates Outperform on Xeris Biopharma Holdings, Raises Price Target to $21

PRO
Piper Sandler Reiterates Neutral on Xeris Biopharma Holdings, Raises Price Target to $12

PRO
HC Wainwright & Co. Maintains Buy on Xeris Biopharma Holdings, Raises Price Target to $18

PRO
Barclays Maintains Overweight on Xeris Biopharma Holdings, Raises Price Target to $14

PRO
Leerink Partners Maintains Outperform on Xeris Biopharma Holdings, Raises Price Target to $16